Company Overview and News

7
SWIR / Sierra Wireless, Inc. FORM 6-K (Current Report of Foreign Issuer)

4h sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
2 IoT Stocks For Your Roth IRA

2018-04-17 seekingalpha
The companies profiled today are on the "Very Short List" of stocks that can lead in the next decade at my investment letter Margin of Safety Investing.
Upvote Downvote

3
Alkermes's stock soars 21% premarket after FDA accepts NDA for review

2018-04-16 marketwatch
Shares of Alkermes PLC soared 21% in premarket trade Monday, after the biopharmaceutical company said the Food and Drug Administration accepted for review the company's new drug application (NDA) for its treatment of major depressive disorder (MDD). The acceptance comes after the FDA had initially issued a "refusal to file" letter for the MDD treatment, ALKS 5461, on March 30. The stock had plunged 22% on April 2, when the news of the letter was released.
Upvote Downvote

 
Exfo Inc (EXFO) Fundamental Valuation Report - Quant Analysis

2018-04-05 valuewalk
This Report was generated using the tools available on StockCalc.com. Patchell Brook Equity Analytics Inc. emphasizes that the user assumes all risks associated with the use of this report or the Stockcalc website including, but not limited to, all terms and conditions mentioned in the legal disclaimer. To access all of the tools on Stockcalc, including more detailed valuation reports and the models used to generate these valuations, please subscribe for a free 30 day trial of Stockcalc here.
Upvote Downvote

 
3 Strong Tech Stocks That Defied Tuesday's Selloff

2018-03-27 zacks
After opening higher on the back of Monday’s strong rebound, stocks tumbled into the red again on Tuesday afternoon. Tech companies led the day’s selloff, with investors continuing to ditch internet companies like Facebook (FB - Free Report) , Twitter (TWTR - Free Report) , and Alphabet (GOOGL - Free Report) in the wake of data privacy concerns.
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. SIERRA WIRELESS, INC. 6-K (Current Report of Foreign Issuer)

2018-03-22 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
Upvote Downvote

 
Financial Exchange Stock Talk: Kirk Spano On Sierra Wireless And Intel

2018-03-20 seekingalpha
We've recently begun a new partnership with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. 6-K (Current Report of Foreign Issuer)

2018-03-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. 40-F

2018-03-07 sec.gov
Document - 1 -
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. SIERRA WIRELESS, INC. 6-K (Current Report of Foreign Issuer)

2018-03-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2018 (Commission File. No. 000-30718). SIERRA WIRELESS, INC. (Translation of registrant’s name in English) 13811 Wireless Way Richmond, British Columbia, Canada V6V 3A4 (Address of principal executive offices and zip code) Registrant’s Telephone Number, including area code: 604-231-1100
Upvote Downvote

 
Canadian tech firms connect at Mobile World Congress

2018-02-28 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. SIERRA WIRELESS, INC. 6-K (Current Report of Foreign Issuer)

2018-02-28 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February 2018 (Commission File. No. 000-30718). SIERRA WIRELESS, INC. (Translation of registrant’s name in English) 13811 Wireless Way Richmond, British Columbia, Canada V6V 3A4 (Address of principal executive offices and zip code) Registrant’s Telephone Number, including area code: 604-231-1100
Upvote Downvote

 
SWIR / Sierra Wireless, Inc. SIERRA WIRELESS, INC. 6-K (Current Report of Foreign Issuer)

2018-02-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 For the Month of February, 2018 (Commission File. No. 000-30718). SIERRA WIRELESS, INC. (Translation of registrant’s name in English) 13811 Wireless Way Richmond, British Columbia, Canada V6V 3A4 (Address of principal executive offices and zip code) Registrant’s Telephone Number, including area code: 604-231-110
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 826516106